NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
30.80
+0.40 (1.32%)
Dec 20, 2024, 4:00 PM EST - Market closed
NovoCure Revenue
NovoCure had revenue of $155.10M in the quarter ending September 30, 2024, with 21.81% growth. This brings the company's revenue in the last twelve months to $577.74M, up 14.63% year-over-year. In the year 2023, NovoCure had annual revenue of $509.34M, down -5.30%.
Revenue (ttm)
$577.74M
Revenue Growth
+14.63%
P/S Ratio
5.73
Revenue / Employee
$397,617
Employees
1,453
Market Cap
3.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Oscar Health | 8.22B |
| Perrigo Company | 4.39B |
| Envista Holdings | 2.50B |
| Inari Medical | 574.50M |
| Veracyte | 425.33M |
| CRISPR Therapeutics AG | 202.83M |
| Rhythm Pharmaceuticals | 112.53M |
| Verona Pharma | 5.62M |
NVCR News
- 17 days ago - NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer - Seeking Alpha
- 19 days ago - Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields - Seeking Alpha
- 19 days ago - NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients - Benzinga
- 19 days ago - Novocure's pancreatic cancer treatment meets main goal in late-stage study - Reuters
- 19 days ago - Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer - Business Wire
- 19 days ago - Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer - Business Wire
- 24 days ago - Novocure to Participate in Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma - Business Wire